A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

William J. Sandborn, Subrata Ghosh, Julián Panés, +58

Clinical Gastroenterology and Hepatology

InflammationChronic Inflammatory DiseasesAnti-inflammatoryCrohn ’Gastrointestinal Pharmacology +7

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)

Silvio Danese, Séverine Vermeire, Paul Hellstern, +14

Gut

Infliximab in severe ulcerative colitis: short‐term results of different infusion regimens and long‐term follow‐up

Anna Kohn, Marco Daperno, Alessandro Armuzzi, +12

Alimentary Pharmacology & Therapeutics

Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen.

Cosimo Prantera, Anna Kohn, R. Mangiarotti, +2

PubMed

The efficacy and safety of a third anti‐TNF monoclonal antibody in Crohn’s disease after failure of two other anti‐TNF antibodies

Matthieu Allez, Séverine Vermeire, Nicolas Mozziconacci, +14

Alimentary Pharmacology & Therapeutics

Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome

Piero Portincasa, Leonilde Bonfrate, Maria Lia Scribano, +10

Journal of Gastrointestinal and Liver Diseases

Infliximab in refractory pouchitis complicated by fistulae following ileo‐anal pouch for ulcerative colitis

Angelo Viscido, F. I. Habib, Anna Kohn, +6

Alimentary Pharmacology & Therapeutics

The Time Course of Diagnostic Delay in Inflammatory Bowel Disease Over the Last Sixty Years: An Italian Multicentre Study

Laura Cantoro, Antonio Di Sabatino, Claudio Papi, +9

Journal of Crohn s and Colitis

Anti-tumour necrosis factor alpha (Infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients

Anna Kohn, Cosimo Prantera, A. Pera, +3

Digestive and Liver Disease

InflammationAnti-inflammatoryAutoimmune DiseaseOpen StudyImmunology +7

Clinical trial: ulcerative colitis maintenance treatment with 5‐ASA: a 1‐year, randomized multicentre study comparing MMX^® with Asacol^®

Cosimo Prantera, Anna Kohn, Massimo Campieri, +8

Alimentary Pharmacology & Therapeutics